CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CATCH project investigates new methods to activate T cells in chronic lymphocytic leukaemia (CLL) to improve the effectiveness of therapies like CAR-T and tri-specific antibodies. It aims to validate these methods through laboratory studies and develop a commercial strategy for their implementation.
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia globally and can rarely be cured.
Despite recent advances, the efficacy of promising autologous T cell-based therapies, such as CAR-T technology and bi-/tri-specific antibodies, has been disappointing.
This stems from a T cell dysfunction in this disease setting: altered T cell skewing, impaired metabolic plasticity, and disrupted T-cell functioning.Prof.
Arnon Kater's group studies alternative activation pathways to overco…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
